# MI Cancer Seek

Source: https://onco.cc/drugs/caris-mi-cancer-seek/  
OnCo record `caris-mi-cancer-seek` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The first FDA-approved test that sequences all of a tumour's genes and gene activity at once, used to match patients to several targeted drugs.

## Summary

Caris Life Sciences' MI Cancer Seek was approved by the FDA in November 2024 as the first companion diagnostic combining whole-exome and whole-transcriptome sequencing, with claims covering several targeted and immune therapies across breast, colorectal, melanoma and lung cancers alongside tumour-profiling claims. The broad readout underpins Caris's real-world database, and the company's argument is that exome-plus-transcriptome captures fusions, expression and signatures that panels miss. Turnaround and tissue requirements are larger than for targeted panels.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-10
- Tags: test
- Brand: MI Cancer Seek
- Modality: Whole-exome and whole-transcriptome companion diagnostic test
- Mechanism: Simultaneous whole-exome DNA and whole-transcriptome RNA sequencing from a single tumour sample, with companion diagnostic claims layered on top of the broad profile.
- Approvals: US 2024: Companion diagnostic claims across several solid tumours, with tumour-profiling claims

## Notes

- What a result means: one sample yields the full genomic picture; the companion claims matter for approved drugs, and the rest supports trial matching.
- Pancreatic ductal adenocarcinoma: the DNA and RNA profiling of 2,483 tumours that produced the KRAS wild-type fusion and immune-marker table was run on this laboratory's platform (Philip 2022).

## Sources

- Caris: MI Cancer Seek (page moved; nearest live section): https://www.carislifesciences.com/products-and-services/molecular-profiling/

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- technologies: [Companion diagnostics](https://onco.cc/technologies/companion-diagnostic/), [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [RNA sequencing & expression profiling](https://onco.cc/technologies/rna-seq/), [Whole-exome & whole-genome sequencing](https://onco.cc/technologies/wes-wgs/)
- companies: [Caris Life Sciences](https://onco.cc/companies/caris/)
- terms: [Next-generation sequencing (NGS)](https://onco.cc/terms/ngs/)
- key papers: [Detection and localization of surgically resectable cancers with a multi-analyte blood test](https://onco.cc/key-papers/paper-cohen-cancerseek-multi-analyte-blood-test-science-2018/), [Molecular biomarkers for the evaluation of colorectal cancer: guideline from ASCP, CAP, AMP and ASCO](https://onco.cc/key-papers/paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017/), [Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma](https://onco.cc/key-papers/paper-philip-kras-wild-type-pancreatic-ccr-2022/)
- biomarkers: [MSI-high (microsatellite instability by PCR or sequencing)](https://onco.cc/biomarkers/msi-high/), [RAS wild-type (extended KRAS and NRAS testing)](https://onco.cc/biomarkers/ras-wild-type/)

---
JSON: https://onco.cc/api/v1/entities/caris-mi-cancer-seek.json